 Kaustav Bera
Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Artificial Intelligence | 8 | 2024 | 381 | 2.380 |
Why?
| | Radiology | 8 | 2026 | 174 | 1.920 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 12 | 2022 | 1192 | 1.010 |
Why?
| | Neoplasms | 6 | 2023 | 2913 | 0.990 |
Why?
| | Radiometry | 3 | 2021 | 56 | 0.860 |
Why?
| | Diagnostic Imaging | 4 | 2025 | 337 | 0.830 |
Why?
| | Cell Movement | 6 | 2025 | 963 | 0.820 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2024 | 30 | 0.810 |
Why?
| | Tomography, X-Ray Computed | 13 | 2024 | 2770 | 0.790 |
Why?
| | Intestinal Mucosa | 2 | 2026 | 675 | 0.780 |
Why?
| | Medical Oncology | 3 | 2024 | 340 | 0.770 |
Why?
| | Publications | 1 | 2023 | 47 | 0.770 |
Why?
| | Lung Neoplasms | 12 | 2022 | 2668 | 0.740 |
Why?
| | Extracellular Fluid | 1 | 2022 | 38 | 0.740 |
Why?
| | Viscosity | 1 | 2022 | 92 | 0.730 |
Why?
| | Prostatic Neoplasms | 3 | 2025 | 981 | 0.710 |
Why?
| | Stem Cells | 1 | 2026 | 630 | 0.680 |
Why?
| | Actomyosin | 4 | 2024 | 20 | 0.650 |
Why?
| | Neoplasm Metastasis | 2 | 2022 | 688 | 0.640 |
Why?
| | Pathology, Clinical | 1 | 2019 | 29 | 0.590 |
Why?
| | Cell Differentiation | 2 | 2026 | 2050 | 0.570 |
Why?
| | rhoA GTP-Binding Protein | 3 | 2025 | 76 | 0.550 |
Why?
| | Precision Medicine | 3 | 2024 | 461 | 0.510 |
Why?
| | Machine Learning | 4 | 2021 | 587 | 0.510 |
Why?
| | Oropharyngeal Neoplasms | 3 | 2022 | 56 | 0.500 |
Why?
| | Glioblastoma | 4 | 2022 | 354 | 0.490 |
Why?
| | Mechanotransduction, Cellular | 3 | 2026 | 121 | 0.480 |
Why?
| | Prognosis | 18 | 2022 | 4330 | 0.440 |
Why?
| | Image Processing, Computer-Assisted | 5 | 2025 | 783 | 0.420 |
Why?
| | Biomarkers, Tumor | 5 | 2022 | 1329 | 0.410 |
Why?
| | Cytoskeleton | 2 | 2026 | 192 | 0.410 |
Why?
| | Organoids | 2 | 2026 | 144 | 0.400 |
Why?
| | Myofibroblasts | 2 | 2025 | 149 | 0.390 |
Why?
| | Papillomavirus Infections | 3 | 2022 | 344 | 0.380 |
Why?
| | Humans | 65 | 2026 | 145783 | 0.380 |
Why?
| | Myosin Type II | 2 | 2025 | 18 | 0.380 |
Why?
| | Sodium-Hydrogen Exchangers | 2 | 2022 | 23 | 0.370 |
Why?
| | Intestines | 2 | 2026 | 354 | 0.370 |
Why?
| | Head and Neck Neoplasms | 3 | 2022 | 561 | 0.360 |
Why?
| | Magnetic Resonance Imaging | 9 | 2024 | 3916 | 0.360 |
Why?
| | Actins | 3 | 2022 | 426 | 0.340 |
Why?
| | Immunotherapy | 3 | 2022 | 668 | 0.340 |
Why?
| | Prostate | 2 | 2024 | 159 | 0.340 |
Why?
| | Alphapapillomavirus | 2 | 2022 | 35 | 0.340 |
Why?
| | Hippocratic Oath | 1 | 2011 | 3 | 0.340 |
Why?
| | Cell Nucleus | 3 | 2026 | 588 | 0.340 |
Why?
| | Hydrogels | 4 | 2026 | 701 | 0.330 |
Why?
| | Image Interpretation, Computer-Assisted | 3 | 2021 | 289 | 0.300 |
Why?
| | Retrospective Studies | 21 | 2024 | 17330 | 0.300 |
Why?
| | Granuloma | 2 | 2021 | 97 | 0.300 |
Why?
| | Physicians | 2 | 2023 | 956 | 0.280 |
Why?
| | Radiologists | 2 | 2026 | 61 | 0.280 |
Why?
| | Neoplasm Staging | 6 | 2025 | 1475 | 0.270 |
Why?
| | Brain Neoplasms | 4 | 2022 | 1331 | 0.270 |
Why?
| | Cell Size | 2 | 2024 | 93 | 0.260 |
Why?
| | Cytoplasm | 2 | 2025 | 254 | 0.250 |
Why?
| | Radiology Information Systems | 2 | 2024 | 35 | 0.250 |
Why?
| | Aged | 20 | 2025 | 26217 | 0.250 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1582 | 0.240 |
Why?
| | Aged, 80 and over | 10 | 2024 | 8347 | 0.240 |
Why?
| | Vimentin | 1 | 2026 | 54 | 0.230 |
Why?
| | Academic Medical Centers | 2 | 2026 | 554 | 0.230 |
Why?
| | Specialty Boards | 1 | 2026 | 42 | 0.230 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 3 | 2024 | 122 | 0.230 |
Why?
| | Survival Analysis | 4 | 2022 | 1378 | 0.230 |
Why?
| | Sodium-Hydrogen Exchanger 1 | 1 | 2024 | 3 | 0.220 |
Why?
| | Aortic Valve Stenosis | 2 | 2025 | 256 | 0.220 |
Why?
| | Tomography, Spiral Computed | 1 | 2024 | 30 | 0.220 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2024 | 21 | 0.210 |
Why?
| | Receptors, Peptide | 1 | 2024 | 18 | 0.210 |
Why?
| | Checklist | 1 | 2026 | 110 | 0.210 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 154 | 0.210 |
Why?
| | Certification | 1 | 2026 | 119 | 0.210 |
Why?
| | Microfilament Proteins | 1 | 2025 | 135 | 0.210 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 72 | 0.210 |
Why?
| | Radiography | 2 | 2023 | 853 | 0.210 |
Why?
| | Pneumothorax | 1 | 2024 | 52 | 0.210 |
Why?
| | Chemoradiotherapy | 3 | 2022 | 239 | 0.210 |
Why?
| | Radiation Exposure | 1 | 2024 | 63 | 0.200 |
Why?
| | Anesthesia, Local | 1 | 2024 | 26 | 0.200 |
Why?
| | Geriatrics | 1 | 2025 | 95 | 0.200 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 41 | 0.200 |
Why?
| | Internship and Residency | 2 | 2026 | 1269 | 0.200 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 165 | 0.200 |
Why?
| | Middle Aged | 19 | 2024 | 36309 | 0.200 |
Why?
| | Phosphoproteins | 1 | 2026 | 337 | 0.200 |
Why?
| | Radiopharmaceuticals | 1 | 2024 | 205 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1450 | 0.200 |
Why?
| | Radiography, Thoracic | 1 | 2024 | 172 | 0.200 |
Why?
| | Adenocarcinoma | 2 | 2022 | 926 | 0.200 |
Why?
| | Elasticity | 1 | 2024 | 189 | 0.200 |
Why?
| | Breast Neoplasms | 3 | 2022 | 2393 | 0.190 |
Why?
| | Physicians, Women | 1 | 2024 | 90 | 0.190 |
Why?
| | Computed Tomography Angiography | 1 | 2024 | 146 | 0.190 |
Why?
| | Societies, Medical | 2 | 2025 | 900 | 0.190 |
Why?
| | Geriatric Assessment | 1 | 2025 | 240 | 0.190 |
Why?
| | Prostate-Specific Antigen | 1 | 2024 | 161 | 0.190 |
Why?
| | Radiation Dosage | 1 | 2024 | 193 | 0.190 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2026 | 426 | 0.190 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2022 | 8 | 0.190 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 119 | 0.190 |
Why?
| | Polyethylene Glycols | 2 | 2026 | 649 | 0.190 |
Why?
| | Traction | 1 | 2022 | 19 | 0.190 |
Why?
| | Faculty, Medical | 1 | 2026 | 305 | 0.190 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 128 | 0.180 |
Why?
| | Chick Embryo | 1 | 2022 | 132 | 0.180 |
Why?
| | Radiography, Dual-Energy Scanned Projection | 1 | 2022 | 7 | 0.180 |
Why?
| | TRPV Cation Channels | 1 | 2022 | 43 | 0.180 |
Why?
| | Neoadjuvant Therapy | 3 | 2020 | 467 | 0.180 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 241 | 0.180 |
Why?
| | Spheroids, Cellular | 1 | 2022 | 74 | 0.180 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2024 | 154 | 0.180 |
Why?
| | Aortic Valve | 1 | 2025 | 364 | 0.180 |
Why?
| | Proto-Oncogene Proteins | 1 | 2025 | 625 | 0.180 |
Why?
| | Mechanical Phenomena | 1 | 2022 | 80 | 0.170 |
Why?
| | Atrial Appendage | 1 | 2022 | 36 | 0.170 |
Why?
| | Leadership | 1 | 2026 | 402 | 0.170 |
Why?
| | Lung | 3 | 2024 | 4116 | 0.170 |
Why?
| | Bile Duct Neoplasms | 1 | 2022 | 131 | 0.160 |
Why?
| | Treatment Outcome | 6 | 2024 | 11794 | 0.160 |
Why?
| | Male | 22 | 2025 | 73011 | 0.160 |
Why?
| | Deglutition Disorders | 1 | 2022 | 154 | 0.160 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2021 | 92 | 0.160 |
Why?
| | Genital Neoplasms, Female | 1 | 2022 | 99 | 0.160 |
Why?
| | Calcinosis | 1 | 2022 | 234 | 0.160 |
Why?
| | Esophageal Neoplasms | 1 | 2024 | 348 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2020 | 311 | 0.150 |
Why?
| | Fibroblasts | 1 | 2025 | 1028 | 0.150 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 61 | 0.150 |
Why?
| | Crohn Disease | 1 | 2023 | 260 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 1150 | 0.140 |
Why?
| | Animals | 7 | 2026 | 38102 | 0.140 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2018 | 25 | 0.140 |
Why?
| | Curriculum | 1 | 2026 | 1074 | 0.140 |
Why?
| | Rectal Neoplasms | 1 | 2020 | 159 | 0.140 |
Why?
| | Female | 23 | 2024 | 79045 | 0.140 |
Why?
| | Pneumonectomy | 1 | 2020 | 167 | 0.140 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1777 | 0.130 |
Why?
| | Zebrafish | 1 | 2022 | 532 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 266 | 0.130 |
Why?
| | Biopsy | 1 | 2021 | 1082 | 0.130 |
Why?
| | Multimodal Imaging | 1 | 2018 | 129 | 0.130 |
Why?
| | Cell Proliferation | 1 | 2024 | 2514 | 0.130 |
Why?
| | Computational Biology | 1 | 2022 | 669 | 0.120 |
Why?
| | Papillomaviridae | 3 | 2022 | 116 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 910 | 0.120 |
Why?
| | Algorithms | 1 | 2024 | 1851 | 0.120 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2933 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 750 | 0.110 |
Why?
| | Survival Rate | 4 | 2021 | 2094 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1271 | 0.110 |
Why?
| | United States | 7 | 2026 | 16126 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 641 | 0.110 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2021 | 427 | 0.110 |
Why?
| | Emergency Service, Hospital | 2 | 2024 | 2383 | 0.110 |
Why?
| | Adult | 13 | 2024 | 40881 | 0.110 |
Why?
| | Aging | 1 | 2025 | 1973 | 0.100 |
Why?
| | Tumor Microenvironment | 3 | 2022 | 735 | 0.090 |
Why?
| | Cytodiagnosis | 2 | 2022 | 31 | 0.090 |
Why?
| | Workflow | 2 | 2023 | 183 | 0.090 |
Why?
| | Lung Diseases | 1 | 2018 | 782 | 0.090 |
Why?
| | Mice | 3 | 2025 | 18356 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1330 | 0.090 |
Why?
| | Extracellular Matrix | 2 | 2026 | 563 | 0.080 |
Why?
| | India | 1 | 2011 | 213 | 0.080 |
Why?
| | Hypoxia | 1 | 2018 | 1199 | 0.080 |
Why?
| | Risk Assessment | 1 | 2020 | 3752 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2191 | 0.080 |
Why?
| | Water | 2 | 2022 | 448 | 0.070 |
Why?
| | ROC Curve | 2 | 2022 | 618 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 2000 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4090 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2021 | 770 | 0.070 |
Why?
| | Brain | 1 | 2021 | 2969 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2025 | 4151 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5428 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 971 | 0.060 |
Why?
| | Contractile Proteins | 1 | 2025 | 13 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 1512 | 0.060 |
Why?
| | Laminin | 1 | 2025 | 72 | 0.060 |
Why?
| | Morphogenesis | 1 | 2026 | 171 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 4302 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3551 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2026 | 451 | 0.050 |
Why?
| | NIH 3T3 Cells | 1 | 2024 | 145 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2123 | 0.050 |
Why?
| | Efficiency | 1 | 2024 | 103 | 0.050 |
Why?
| | Azacitidine | 1 | 2025 | 157 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2025 | 508 | 0.050 |
Why?
| | Light | 1 | 2026 | 403 | 0.050 |
Why?
| | Accreditation | 1 | 2023 | 101 | 0.050 |
Why?
| | High-Throughput Screening Assays | 1 | 2025 | 177 | 0.050 |
Why?
| | Barium | 1 | 2022 | 27 | 0.050 |
Why?
| | Dimethylpolysiloxanes | 1 | 2022 | 9 | 0.050 |
Why?
| | Pathologists | 1 | 2022 | 19 | 0.050 |
Why?
| | Educational Measurement | 1 | 2026 | 326 | 0.050 |
Why?
| | Bile Ducts | 1 | 2022 | 68 | 0.050 |
Why?
| | Bevacizumab | 1 | 2023 | 168 | 0.050 |
Why?
| | Fibrosis | 1 | 2025 | 561 | 0.050 |
Why?
| | Anisotropy | 1 | 2022 | 74 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2022 | 73 | 0.040 |
Why?
| | Ileum | 1 | 2023 | 112 | 0.040 |
Why?
| | Speech | 1 | 2022 | 76 | 0.040 |
Why?
| | Ion Channels | 1 | 2022 | 129 | 0.040 |
Why?
| | Hematoxylin | 1 | 2021 | 8 | 0.040 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2021 | 10 | 0.040 |
Why?
| | Ventilators, Mechanical | 1 | 2021 | 71 | 0.040 |
Why?
| | Nomograms | 1 | 2021 | 59 | 0.040 |
Why?
| | Prostatectomy | 1 | 2021 | 94 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2024 | 560 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 6033 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 223 | 0.040 |
Why?
| | Language | 1 | 2023 | 324 | 0.040 |
Why?
| | Polymers | 1 | 2024 | 485 | 0.040 |
Why?
| | Nuclear Envelope | 1 | 2019 | 45 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2019 | 103 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2018 | 33 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 149 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 562 | 0.030 |
Why?
| | Pulmonary Artery | 1 | 2024 | 1129 | 0.030 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2019 | 179 | 0.030 |
Why?
| | Forecasting | 1 | 2020 | 390 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 733 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1898 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3170 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 10919 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2022 | 1134 | 0.030 |
Why?
| | Calcium | 1 | 2022 | 1191 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 948 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 644 | 0.030 |
Why?
| | Clinical Competence | 1 | 2023 | 1247 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2865 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5224 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2023 | 1101 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1491 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 14254 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2024 | 6465 | 0.020 |
Why?
| | Genomics | 1 | 2018 | 830 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2024 | 2977 | 0.020 |
Why?
| | Infant | 1 | 2024 | 10091 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 8078 | 0.020 |
Why?
| | Adolescent | 1 | 2018 | 22577 | 0.010 |
Why?
|
|
Bera's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|